Overview

Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
2012-06-22
Target enrollment:
Participant gender:
Summary
The objective of this clinical investigation is to determine the most effective drug concentration(s) of BOL-303259-X in the reduction of IOP in order to support further clinical development of an appropriate dose with regard to efficacy, and ocular and systemic safety.
Phase:
Phase 2
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Treatments:
Latanoprost
Ophthalmic Solutions
Pharmaceutical Solutions